Salud financiera de hoja de balance de Astria Therapeutics
Salud financiera controles de criterios 6/6
Astria Therapeutics tiene un patrimonio de los accionistas total de $347.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $368.0M y $20.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$354.70m |
| Patrimonio | US$347.08m |
| Total pasivo | US$20.91m |
| Activos totales | US$367.99m |
Actualizaciones recientes sobre salud financiera
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Recent updates
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Jul 11Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
Jun 24Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout
Feb 04We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Dec 10We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
Jul 27We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate
Apr 03Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation
Nov 30We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely
Aug 01Dr. Chris Morabito is the new medical chief of Astria Therapeutics
Jul 15Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
Jun 30Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital
Jun 15Catabasis Pharma shares surge after Quellis Biosciences deal
Jan 29Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?
Dec 10
Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 29Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($357.9M) de ATXS superan a sus pasivos a corto plazo ($16.4M).
Pasivo a largo plazo: Los activos a corto plazo de ATXS ($357.9M) superan a sus pasivos a largo plazo ($4.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ATXS está libre de deudas.
Reducción de la deuda: ATXS no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ATXS tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ATXS dispone de suficiente cash runway para 2.6 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 17.3% cada año.